ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IRTC
ICUI (56) NVST (46) PLSE (39) HTFL (53) ⌘ Pro Terminal →

iRhythm Holdings Inc. (IRTC) — RQD Stock Rating Cockpit

$126.17 +2.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $126.45

iRhythm Holdings Inc. (IRTC) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.07B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, iRhythm Holdings Inc. (NASDAQ: IRTC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $126.17 (+2.27% 1D, market cap $4.07B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IRTC ranks #297 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRTC compare to ICUI and NVST in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), IRTC carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 70.6%, and ROIC of -13.5%. By comparison, ICUI (ICU Medical Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC 1.0%, cap $4.10B) and NVST (Envista Holdings Corporation) posts a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRTC?
▼

Per IRTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388658), iRhythm Holdings Inc. generated $747.1M in revenue (+26.2% YoY), -$45.0M in net income, and $34.5M in free cash flow against $1.02B in total assets and $390.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $126.45 (+0.22%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 4.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Cash (12)Whales (11)SEC (9)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$202 Bull$120 Base$94 Bear
📬 FREE IRTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRTC)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY IRTC SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 4.6% FCF Margin ($34.5M FCF) & 70.6% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±7.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit6/20 pts (-14 pt drag)

Macro rate sensitivity & RSI-14 (58.9) create a -14 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$106.05+7.1% Next Q
Q2 (-2Q)
42
Grade D$113.55+9.2% Next Q
Q3 (-1Q)
44
Grade D$123.99+1.8% Next Q
Current
47
Grade D$126.17-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRTC currently carries a cautious 47/100 (D) rating due to Macro Regime Fit (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($115.08) and Max Pain ($132.48) forces dealer call-delta covering toward $202.09.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRTC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
58.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.01>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE28% OF RANGE
L: $101$126.17H: $192
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (70.6% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on IRTC

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

-13.5% ROIC with 70.6% gross margin and 0.82% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (45)

Altman-Z 3.01 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

20/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like IRTC
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRTC)

  • ✓Walkthrough of IRTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IRTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.87%⚡ TESTING RESISTANCE
2026-11-03O $127.8H $127.8L $123.4C $126.2VOL 533.5K
RES: $128.2SUP: $99.12SMA50: $115.1SMA200: $121.8
$161.2$144.8$128.4$112.0$95.61RES $128.2SUP $99.12$126.22026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRTC Butterfly Map → + Track IRTC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
23.1%/yr Implied 5Y Growth

vs. +26.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IRTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRTC)

Health Care Rank #297 of 1015 ⚔️ ICUI vs IRTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRTC vs. ICUI, NVST, PLSE, HTFL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, iRhythm Holdings Inc. (IRTC) ranks #297 by composite RQD confidence (47/100, grade D) and #177 by equity capitalization ($4.07B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ICUI currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with IRTC at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IRTC ACTIVE
iRhythm Holdings Inc.
D 47/100 — 70.6% -13.5% +2.27% $4.07B Benchmark Subject
ICUI
ICU Medical Inc.
D+ 56/100 — 36.8% 1.0% -0.85% $4.10B /icui-vs-irtc →
NVST
Envista Holdings Corporation
D 46/100 84.1x 54.7% 5.1% +5.10% $3.78B /nvst-vs-irtc →
PLSE
Pulse Biosciences Inc
D- 39/100 — -30.0% -30.7% +1.26% $3.73B /plse-vs-irtc →
HTFL
Heartflow Inc.
D+ 53/100 — 76.8% -12.0% -7.72% $5.13B /htfl-vs-irtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001388658 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iRhythm Holdings Inc. (IRTC) reported GAAP revenue of $747.1M (+26.2% vs. FY2024 revenue of $591.8M , and +51.6% cumulative change since FY2023) , GAAP net income of -$45.0M, operating cash flow of $80.9M, and free cash flow of $34.5M (+213.0% YoY). On the balance sheet, IRTC closed FY2025 with $1.02B in total assets against $390.3M in total debt (Altman Z-Score: 3.01, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $747.1M -$45.0M $80.9M $34.5M $1.02B $390.3M
FY2024 (FY) 2024-12-31 $591.8M -$113.0M $3.4M -$30.6M $931.4M $378.2M
FY2023 (FY) 2023-12-31 $492.7M -$123.0M -$50.1M -$72.3M $2.32B $542.2M

3. IRTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, iRhythm Holdings Inc. (NASDAQ: IRTC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $126.17 (+2.27% 1D, market cap $4.07B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IRTC ranks #297 in composite RQD confidence.

How does IRTC compare to ICUI and NVST in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IRTC carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 70.6%, and ROIC of -13.5%. By comparison, ICUI (ICU Medical Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC 1.0%, cap $4.10B) and NVST (Envista Holdings Corporation) posts a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRTC?

Per IRTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388658), iRhythm Holdings Inc. generated $747.1M in revenue (+26.2% YoY), -$45.0M in net income, and $34.5M in free cash flow against $1.02B in total assets and $390.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRTC trading relative to its 50-day, 200-day, and 52-week technical levels?

IRTC last traded at $126.17 (+2.27% on volume of 918,256 shares), positioning the stock +9.64% above its 50-day simple moving average ($115.08) and +3.63% above its 200-day simple moving average ($121.75). Across its 52-week range of $100.70 to $192.47, IRTC sits at the 27.8% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($116.33 to $136.01).

Direct Sub-Reports: IRTC RQD Cockpit IRTC 12M Forecast IRTC Earnings & Move IRTC Dividends & DRIP IRTC Insiders & 13F IRTC Whale Options IRTC Profit Sankey IRTC News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

IRTC — iRhythm Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

iRhythm Holdings Inc. (IRTC) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $126.17 (+2.27% 1D, market capitalization $4.07B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -13.5%, gross margin of 70.6%, operating margin of -7.7%, and free cash flow yield of 0.82%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (9/20): Incorporates a 0.98x equity beta, Altman Z-Score of 3.01, Piotroski F-Score of 7/9, and Debt/Equity of 2.38x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. FY 2025 revenue was $747.1M. Per the market data, gross margin is 70.6%. —: a detailed description of products, customer segments, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), iRhythm Holdings Inc. (IRTC) reported $747.1M in annual revenue (up from $591.8M in FY2024, +26.2% YoY) and -$45.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($492.7M revenue, -$123.0M net income) through FY2025, IRTC scaled operating cash flow to $80.9M and free cash flow to $34.5M, backed by $1.02B in total assets against $390.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.82% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $100.70 – $192.47 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.7% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream links and no proprietary signals. The news flow does reference the VitalConnect acquisition and Zio MCT questions, which point to portfolio and product-line dependencies, but the source does not specify the supply-chain mechanics. Investors should watch whether the VitalConnect integration affects revenue and margin trajectory against the stated 2027 target.

  • Key Question #1: Can IRTC sustain or expand its -7.7% operating margin and -13.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $747.1M and free cash flow of $34.5M, how will capital allocation balance growth reinvestment against $390.3M in total debt?
  • Key Question #3: How sensitive is IRTC's 30.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

IRTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iRhythm Holdings Inc. (IRTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IRTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IRTC Bull vs. Bear Conversation Board — What's Your Call at $126.17?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRTC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IRTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $157.91 (+28.0%)
📌 Pinned Debate

Revenue grew from $492.7M to $747.1M over FY 2023–FY 2025 while operating losses narrowed from -$125.2M to -$57.4M, and Piper Sandler h

Picked up a starter position in IRTC in my $100K Virtual Cash book at $123.37. Revenue grew from $492.7M to $747.1M over FY 2023–FY 2025 while operating losses narrowed from -$125.2M to -$57.4M, and Piper Sandler has an Overweight rating with a $160 price target.. Trading inside a $100.70–$192.47 52-week range with 0.82% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — IRTC's 9/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $106.10 (-14.0%)
Spot @ $123.37

ROIC of -13.5%, FCF yield of 0.82%, and Debt/Equity of 2.38 combined with a Roarable Sell verdict and a 52-week low of $100.70 point to

Fading this rally in IRTC at $123.37. ROIC of -13.5%, FCF yield of 0.82%, and Debt/Equity of 2.38 combined with a Roarable Sell verdict and a 52-week low of $100.70 point to weak cash returns and elevated leverage.. With a beta of 0.98 and the stock sitting at $123.37 (52-wk range $100.70–$192.47), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%